Page 38 - Risk Evaluation News Today

Sorry, ladies, we're just collateral damage.

The rulings from federal judges in Texas and Washington were issues less than 20 minutes apart, the Justice Department said.

On Monday afternoon, the Justice Department called the ruling “extraordinary and unprecedented” and asked a federal appeals court to put the decision on hold.

On Friday, Attorney General Ellen Rosenblum announced that a federal judge in Washington state barred the Food & Drug Administration (FDA) from doing anything to reduce the availability of the

Oregon and Washington win countersuit as another judge in Texas overturns FDA approval from two decades ago. Rosenblum says U.S. Supreme Court may end up with untying the legal knot.

The Texas judge’s ruling was quickly contradicted by another federal judge in Washington State who ordered the F.D.A. to keep mifepristone available.

This issue brief details the Alliance of Hippocratic Medicine challenge to the FDA's approval of the abortion pill, mifepristone. It provides context for the challenge, as well as what some of the possible rulings in the case could mean for access to medication abortion.

This policy watch explains the two conflicting rulings on the provision of mifepristone issued by two separate District Courts on April 7, 2023, Alliance for Hippocratic Medicine v. FDA and State of Washington v. United States Food and Drug Administration.

The drug will continue to be available at least in the short-term since the Texas judge, Matthew Kacsmaryk, stayed his own order for seven days to give the FDA time to ask an appeals court to intervene.

AOC can't insist that "nobody is above the law" when Trump is charged, and then suggest ignoring a judge regarding abortion pills.